Stay updated with breaking news from Multi Parametric Optimization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
As part of our SLAS Europe 2022 coverage, we speak to Sree Vadlamudi from Iktos, about how we can adopt AI to help foster productivity within pharmaceutical research.
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design and Sygnature Discovery, a leading integrated drug discovery CRO headquartered in Nottingham, UK, with expertise across
Iktos, a company specialized in Artificial Intelligence for new drug design today announced recent collaboration agreement in AI for new drug design with Jiangsu Hengrui Pharmaceuticals Co., Ltd., a
PARIS--(BUSINESS WIRE)--Iktos, a company specialized in Artificial Intelligence for new drug design today announced collaboration agreement in AI for new drug design with Chiesi Group, the international research-focused pharmaceutical and healthcare. Under the agreement, Iktos’s de novo generative design software Ma...
Iktos Announces Collaboration With Pfizer in AI for Drug Design Iktos announced today the application of Iktos Artificial Intelligence technology for de novo design to selected Pfizer small-molecule discovery programs. Over the last few years, phenomenal advances in AI algorithmic development and computational power have enabled innovative approaches in small-molecule drug design. Iktos has been at the forefront of these efforts putting its generative modeling technology at work in several collaborations with pharmaceutical and biotechnology companies. A key aspect of the technology is that e...